These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3609504)

  • 21. Carbohydrate enriched diets and bacterial glycosidases in rat faeces.
    Cenci G; Caldini G; Mastrandrea V; Votoni MR
    Microbios; 1993; 76(308):143-51. PubMed ID: 8302195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Faecal mucinase activity assessed in inflammatory bowel disease using 14C threonine labelled mucin substrate.
    Dwarakanath AD; Campbell BJ; Tsai HH; Sunderland D; Hart CA; Rhodes JM
    Gut; 1995 Jul; 37(1):58-62. PubMed ID: 7672682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes of faecal microbiota in patients with Crohn's disease treated with an elemental diet and total parenteral nutrition.
    Shiga H; Kajiura T; Shinozaki J; Takagi S; Kinouchi Y; Takahashi S; Negoro K; Endo K; Kakuta Y; Suzuki M; Shimosegawa T
    Dig Liver Dis; 2012 Sep; 44(9):736-42. PubMed ID: 22622202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding of Coprococcus comes to the Fc portion of IgG. A possible role in the pathogenesis of Crohn's disease?
    Van de Merwe JP; Stegeman JH
    Eur J Immunol; 1985 Aug; 15(8):860-3. PubMed ID: 3896820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum agglutinins to Eubacterium and Peptostreptococcus species in Crohn's and other diseases.
    Wensinck F; Van de Merwe JP
    J Hyg (Lond); 1981 Aug; 87(1):13-24. PubMed ID: 7019318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucin degradation in human colon ecosystems. Isolation and properties of fecal strains that degrade ABH blood group antigens and oligosaccharides from mucin glycoproteins.
    Hoskins LC; Agustines M; McKee WB; Boulding ET; Kriaris M; Niedermeyer G
    J Clin Invest; 1985 Mar; 75(3):944-53. PubMed ID: 3920248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease.
    Carrette O; Favier C; Mizon C; Neut C; Cortot A; Colombel JF; Mizon J
    Dig Dis Sci; 1995 Dec; 40(12):2641-6. PubMed ID: 8536525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Serodiagnosis of Crohn's disease].
    Auer IO; Wensinck F; Röder A; Merwe JP; Schmidt H; Schuster S
    Dtsch Med Wochenschr; 1983 Aug; 108(33):1242-6. PubMed ID: 6872878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Decrease of fecal beta-galactosidase activity in Crohn disease].
    Canva-Delcambre V; Soenen V; Mizon C; Cortot A; Mizon J; Colombel JF
    Gastroenterol Clin Biol; 1993; 17(10):718-22. PubMed ID: 8288080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of a soluble bacterial carbohydrate fraction on the viscosity of intestinal contents in healthy subjects and patients with Crohn's disease.
    Hazenberg MP; Pennock-Schröder AM; Wensinck F; Van de Merwe JP
    Eur J Clin Invest; 1989 Feb; 19(1):61-4. PubMed ID: 2499463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular inventory of faecal microflora in patients with Crohn's disease.
    Mangin I; Bonnet R; Seksik P; Rigottier-Gois L; Sutren M; Bouhnik Y; Neut C; Collins MD; Colombel JF; Marteau P; Doré J
    FEMS Microbiol Ecol; 2004 Oct; 50(1):25-36. PubMed ID: 19712374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Culturing and extraction of Coprococcus comes, absorption of serumagglutinins by soluble fractions and relation between agglutinins and antibodies in sera of patients with Crohn's disease.
    Hazenberg MP; Pennock-Schröder AM; van de Merwe JP
    Med Microbiol Immunol; 1986; 175(5):299-306. PubMed ID: 3762491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Qualitative differences in faecal alpha-1-antitrypsin in patients with Crohn's disease.
    Colombel JF; Mizon C; Balduyck M; Cortot A
    Gut; 1989 Feb; 30(2):279-80. PubMed ID: 2784776
    [No Abstract]   [Full Text] [Related]  

  • 34. Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease.
    Takahashi K; Nishida A; Fujimoto T; Fujii M; Shioya M; Imaeda H; Inatomi O; Bamba S; Sugimoto M; Andoh A
    Digestion; 2016; 93(1):59-65. PubMed ID: 26789999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The physiological activity of the intestinal flora in patients with Crohn's disease studied by inoculation of germfree rats.
    Bergstrand LO; Gustafsson BE; Holmström B; Norin KE
    Acta Chir Scand; 1981; 147(8):711-5. PubMed ID: 7046317
    [No Abstract]   [Full Text] [Related]  

  • 36. Mutagenic activation of biliary metabolites of benzo(a)pyrene by beta-glucuronidase-positive bacteria in human faeces.
    Nanno M; Morotomi M; Takayama H; Kuroshima T; Tanaka R; Mutai M
    J Med Microbiol; 1986 Dec; 22(4):351-5. PubMed ID: 3795254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proceedings: The faecal flora of patients with Crohn's disease.
    Wensinck F
    Antonie Van Leeuwenhoek; 1975; 41(2):214-5. PubMed ID: 1080400
    [No Abstract]   [Full Text] [Related]  

  • 38. The resident faecal flora is determined by genetic characteristics of the host. Implications for Crohn's disease?
    Van de Merwe JP; Stegeman JH; Hazenberg MP
    Antonie Van Leeuwenhoek; 1983 Jun; 49(2):119-24. PubMed ID: 6684413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum antibodies to peptidoglycan-polysaccharide complexes from the anaerobic intestinal flora in patients with Crohn's disease.
    Hazenberg MP; de Visser H; Bras MJ; Prins ME; van de Merwe JP
    Digestion; 1990; 47(3):172-80. PubMed ID: 2083802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacterial bile metabolising gene abundance in Crohn's, ulcerative colitis and type 2 diabetes metagenomes.
    Labbé A; Ganopolsky JG; Martoni CJ; Prakash S; Jones ML
    PLoS One; 2014; 9(12):e115175. PubMed ID: 25517115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.